Thermo Fisher Scientific Inc.
General ticker "TMO" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $185.7B (TTM average)
Thermo Fisher Scientific Inc. follows the US Stock Market performance with the rate: 63.4%.
Estimated limits based on current volatility of 1.5%: low 467.83$, high 482.34$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (semi-annually): last record date 2026-03-13, amount 0.47$ (Y0.20%)
- Total employees count: 125000 as of 2024
- US accounted for 50.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Economic downturns and volatility, Geopolitical risks, Public health crises, Market competition, Supply chain disruptions
- Current price 10.3% below estimated low
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [485.58$, 683.22$]
- 2025-12-31 to 2026-12-31 estimated range: [524.00$, 728.86$]
Financial Metrics affecting the TMO estimates:
- Negative: with PPE of 23.9 at the end of fiscal year the price was high
- Positive: 7.67 < Operating profit margin, % of 17.87
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.11 > 6.11
- Positive: 42.68 < Shareholder equity ratio, % of 50.95 <= 64.29
- Positive: Industry inventory ratio change (median), % of -0.93 <= -0.16
- Negative: negative Industry operating income (median)
- Positive: Inventory ratio change, % of -0.58 <= 0
- Negative: 0.73 < Interest expense per share per price, % of 0.83
Short-term TMO quotes
Relationship graph
Long-term TMO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $44,915.00MM | $42,857.00MM | $42,879.00MM |
| Operating Expenses | $36,522.00MM | $35,998.00MM | $35,217.00MM |
| Operating Income | $8,393.00MM | $6,859.00MM | $7,662.00MM |
| Non-Operating Income | $-558.00MM | $-561.00MM | $-667.00MM |
| Interest Expense | $726.00MM | $1,375.00MM | $1,654.00MM |
| R&D Expense | $1,471.00MM | $1,337.00MM | $1,390.00MM |
| Income(Loss) | $7,835.00MM | $6,298.00MM | $6,995.00MM |
| Taxes | $703.00MM | $284.00MM | $657.00MM |
| Other Income(Loss) | $-172.00MM | $-59.00MM | $0.00MM |
| Profit(Loss)* | $6,950.00MM | $5,995.00MM | $6,335.00MM |
| Stockholders Equity | $43,978.00MM | $46,735.00MM | $49,584.00MM |
| Inventory | $5,634.00MM | $5,088.00MM | $4,978.00MM |
| Assets | $97,154.00MM | $98,726.00MM | $97,321.00MM |
| Operating Cash Flow | $9,154.00MM | $8,406.00MM | $8,667.00MM |
| Capital expenditure | $2,243.00MM | $1,479.00MM | $1,400.00MM |
| Investing Cash Flow | $-2,159.00MM | $-5,142.00MM | $-5,841.00MM |
| Financing Cash Flow | $-2,810.00MM | $-3,622.00MM | $-6,792.00MM |
| Earnings Per Share** | $17.73 | $15.53 | $16.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.